KOSDAQBiotech & Pharma317690

QuantaMatrix Incorporated

₩1,643▲ 0.18%2026-11-18 close
Market Cap
₩33.1B
Turnover
₩45,944,837
Volume
30K
Shares out.
20.1M
PER
—
PBR
1.2×
EPS
-₩918
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

dRAST-Led Sales, Persistent Losses and a Restructuring Test

QuantaMatrix has recorded losses for five straight quarters through the third quarter of 2026 on a dRAST-centered revenue base. A KRW 36 billion perpetual convertible bond reduced financial risk, but whether the business restructuring works is the next test.

  1. 1

    Revenue rose 47.7% year on year to KRW 3.69 billion in 2025, yet the operating loss of KRW 15.6 billion extended a four-year run of losses.

  2. 2

    Third-quarter 2026 revenue fell 32.0% from a year earlier to KRW 666 million, and the operating loss of KRW 3.88 billion marks five straight loss-making quarters.

  3. 3

    A KRW 36 billion perpetual convertible bond lifted total equity to KRW 40 billion at end-2025, and reports said it reduced the risk of designation as a managed stock.

  4. 4

    The registered business scope now covers CDMO, cosmetics, health functional foods and CRO, but eight of 18 business purposes were not in operation as of the first half of 2026.

  5. 5

    The conversion period opens on December 30, 2026, and full conversion could issue about 8.31 million shares (29.81%).

02

Business structure

QuantaMatrix Incorporated has developed and manufactured in-vitro diagnostic devices and reagents since 2010, selling them to tertiary hospitals and testing laboratories in Korea and abroad.

Its core product is dRAST, a rapid antimicrobial susceptibility testing system built on microbial diagnostic technology and aimed at the final stage of sepsis diagnosis. Press reports put roughly 99% of company revenue from dRAST, so dependence on a single product is high.

Recurring sales build up only after hospitals install the instrument and run more tests, which drives kit purchases.

The company also runs a molecular immunology multiplex diagnostic platform, and Alzplus, an Alzheimer's diagnostic assist kit, made its first sale in 2025. uRAST, which combines blood culture, microbial identification and susceptibility testing into one process, had its clinical results published in Nature.

At the September 2026 extraordinary shareholders' meeting, the company amended its articles to add pharmaceutical CDMO, cosmetics, health functional foods and brain health and wellness, and widened its testing business to include CRO.

Cosmetics and aesthetics and in-vitro diagnostic device distribution are the first priorities, while CDMO and CRO are not yet active. Eight of the 18 business purposes in the articles were not being pursued as of the first half of 2026.

Production capacity is described around microbial and molecular immunology products, and no plan for new or acquired production facilities had been disclosed as of end-June 2026. With revenue concentrated in one product, how far the new businesses change the revenue mix is the central structural question.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1B-₩3.7B−379.5%
2025Q4₩800M-₩4.6B−579.3%
2026Q1₩700M-₩4B−556.1%
2026Q2₩600M-₩4.2B−652.7%
2026Q3₩700M-₩3.9B−582.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.3B-₩20B-₩19.2B−1556.7%−48.2%14.3%
2023₩3.1B-₩22.4B-₩21.6B−720.0%−119.0%25.1%
2024₩2.5B-₩16.1B-₩20.2B−646.7%−308.8%310.8%
2025₩3.7B-₩15.6B-₩19.5B−421.8%−48.6%31.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a DART-filed basis, revenue rose from KRW 1.29 billion in 2022 to KRW 3.12 billion in 2023 (up 142.5% year on year), fell to KRW 2.5 billion in 2024 (down 19.9%), and reached KRW 3.69 billion in 2025 (up 47.7%), the largest year in the 2022 to 2025 period.

The operating loss was KRW 20 billion in 2022, KRW 22.4 billion in 2023, KRW 16.1 billion in 2024 and KRW 15.6 billion in 2025, a four-year run of losses from 2022 through 2025. The loss peaked in 2023 and narrowed in 2024 and 2025, and the operating margin moved from -1,556.7% in 2022 to -421.8% in 2025.

Revenue grew faster than losses shrank in relative terms, but revenue is still far below the operating loss, so the path to a healthier income structure remains open.

Net loss attributable to controlling shareholders was KRW 19.2 billion in 2022, KRW 21.6 billion in 2023, KRW 20.2 billion in 2024 and KRW 19.5 billion in 2025, and the net loss including non-controlling interests followed the same pattern.

The debt-to-equity ratio jumped to 310.8% in 2024, a period when reports said total equity was about KRW 6.5 billion at year-end 2024.

The perpetual convertible bonds were fully recognized as equity, lifting total equity to KRW 40 billion at end-2025, with total liabilities of KRW 12.7 billion and a debt ratio of 31.7%.

Operating cash flow was negative in every year, at -KRW 16.6 billion in 2022, -KRW 20.7 billion in 2023, -KRW 12.9 billion in 2024 and -KRW 15.1 billion in 2025.

Quarterly revenue went from KRW 980 million in the third quarter of 2025 to KRW 794 million, KRW 726 million and KRW 646 million, then KRW 666 million in the third quarter of 2026, which was down 32.0% from a year earlier.

Operating losses over the same five quarters were KRW 3.72 billion, KRW 4.6 billion, KRW 4.04 billion, KRW 4.22 billion and KRW 3.88 billion, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 18.3 billion.

R&D spending in the first half of 2026 was KRW 2.8 billion, equal to 135.6% of revenue, so development costs continue to exceed sales.

05

Industry analysis

The sepsis diagnostics market is expanding as antimicrobial resistance becomes a larger problem, and according to data the company cited, sepsis incidence has been rising about 8.7% a year.

Demand comes mainly from tertiary hospitals and testing laboratories, and kit revenue builds only after instruments are installed and test volumes grow. Installation within hospitals and insurance and procurement procedures set the pace at which instruments are adopted, which in turn determines growth.

A company official said conventional medical equipment and diagnostic kit businesses have structurally limited short-term growth.

The company says dRAST is optimized for laboratory settings and cites the Nature publication of uRAST clinical results and funding from the US CARB-X program as evidence of technical validation. That assessment rests on company statements, so hospital adoption and unit sales need to be confirmed alongside it.

There is a lag between technical validation and revenue: according to the company, performance verification, clinical work, approval and hospital adoption must all follow development. In the US, the target for an FDA submission is the fourth quarter of 2026, so US sales depend on steps that come after approval.

Cosmetics and aesthetics follow different demand cycles from diagnostic instruments, so the new businesses do not share the same industry conditions.

The company positions itself in the narrow niche of rapid antimicrobial susceptibility testing, where it argues for a technical lead, but independent confirmation of that market's size is limited beyond company statements.

06

Outlook

The nearest milestone the company has set is the approval and launch of dRAST evo. The company says it has cut dRAST evo's cost to roughly 60% to 70% of the prior level and plans to launch it after approval by late 2026.

For the US, the company has set a target of submitting for FDA approval in the fourth quarter of 2026. Under a government program selected in July 2025, the company secured about KRW 5.7 billion in support funding.

The first-half 2026 semiannual report lists rapid blood culture identification, identification and uCLIA development as the upcoming new businesses.

On funding, KRW 28 billion of the KRW 36 billion raised at the end of 2025 remained unused, and the company said it is not considering a convertible bond or rights offering solely to add new businesses.

The next capital-structure variable is conversion from December 30, 2026, and full conversion could change the largest shareholder's stake. The company plans to change its name to QuantaMatrix-linked Cumico in 2027.

The next checkpoints are therefore whether dRAST revenue recovers in the fiscal 2026 annual report, the size of the operating loss, and how the share count changes after conversion.

07

Valuation

PER
—
PBR
1.2×
ROE
-106.8%
EPS
-₩918
BPS
₩1,356
Dividend per share
₩0

PER cannot be calculated because the last four quarters show net losses, so earnings-based multiples offer no comparison. The price-to-book ratio sits above the value of book net assets, which means the stock trades at a premium to net asset value.

Total equity expanded sharply at the end of 2025, enlarging the asset base, but while losses continue that equity has not yet translated into profit. The dividend yield is effectively zero, so there is currently no shareholder return element, and it sits below the industry average.

In March 2026, the independent research firm Valuefinder said dRAST unit sales and revenue growth would be the key indicators for assessing the company's value. If the perpetual convertible bonds convert, about 8.31 million new shares would be issued, so per-share metrics will change after that point.

The valuation reading at this stage therefore centers on revenue growth and the operating loss trend rather than earnings multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

dRAST evo cost reduction and launch plan

About 99% of company revenue comes from dRAST. The company says it has cut the cost of the next-generation dRAST evo to 60% to 70% of the previous level and plans to launch it after approval by late 2026.

Because kit sales recur once instruments are installed and tested, the bull case strengthens as hospital adoption grows. These are company plans, however, and approval outcomes and sales pace have not yet been confirmed.

Capital strengthened by KRW 36 billion perpetual convertible bond

The KRW 36 billion perpetual convertible bond, decided on December 22, 2025, was fully recognized as equity and lifted total equity to about KRW 40 billion. Reports said this eased the accumulated loss ratio issue and reduced the risk of designation as a managed stock.

By the first half of 2026, KRW 8 billion had been spent on R&D and wages, leaving KRW 28 billion unused. The ability to fund product approvals and the business transition while cash remains is a bull point.

Pipeline expansion and government support

Alzplus began its first sales in 2025, and the company expects adoption by five major contract testing organizations and health screening centers in 2026.

Clinical results for uRAST were published in Nature, and in July 2025 the company was selected for a bio-industry technology program, securing about KRW 5.7 billion in government support. The company also cites funding from the US CARB-X program as evidence of technical validation.

Revenue contribution remains small, but a product line beyond dRAST offers room to reduce product concentration.

09

Bear factors

Five straight loss-making quarters and falling sales

Operating losses have continued from the third quarter of 2025 through the third quarter of 2026, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 18.3 billion. Third-quarter 2026 revenue of KRW 666 million was down 32.0% from a year earlier.

First-half 2026 revenue of KRW 1.4 billion fell 28.4% year on year, while the operating loss widened 14% to KRW 8.3 billion. A structure in which R&D spending exceeds revenue on a small sales base is the bear point.

Doubts over the effectiveness of the business restructuring

As of the first half of 2026, 8 of the 18 business purposes in the articles were not being pursued, and the CDMO and CRO businesses added at the September 2026 extraordinary shareholders' meeting are not yet active.

Cosmetics and aesthetics, the first priority, requires a manufacturing base, yet no new or acquired production facility plan had been disclosed as of end-June 2026. Even after development ends, dRAST-type products must pass performance verification, approval and hospital adoption, which takes time. Whether the new businesses can produce near-term revenue is uncertain, and that is the bear point.

Accumulated loss ratio history and possible share conversion

The accumulated loss ratio history rose every year from KRW 14.7 billion in 2020 to KRW 21.6 billion in 2023, which reports attributed mainly to costs far exceeding revenue. At the end of 2025, control passed to a technology investment fund backed by a KOSDAQ-listed company.

If the bonds fully convert after the conversion period opens on December 30, 2026, about 8.31 million shares (29.81%) would be issued and the largest shareholder could change. The capital raise reduced financial risk, but the change in share structure dilutes the value of existing shareholders' stakes.

10

Risk factors

Funding and dilution

If the perpetual convertible bonds fully convert, about 8.31 million shares would be issued, increasing the share count and changing per-share metrics. The company said it is not considering further convertible bonds or rights offerings solely for new businesses.

However, with operating losses running for five quarters, the pace at which the KRW 28 billion unused balance is spent is the key variable for the funding plan.

Regulatory approval and timing

The company's targets are approval and launch of dRAST evo by late 2026 and an FDA submission in the fourth quarter of 2026. Delays would push back both new product revenue and the timing of US market entry.

Diagnostic devices require lengthy clinical validation and hospital adoption, so schedule risk is structurally high.

Revenue concentration and business transition

Roughly 99% of revenue comes from dRAST, leaving high dependence on one product. Revenue fell 19.9% in 2024 and 32.0% year on year in the third quarter of 2026. If new businesses such as cosmetics and aesthetics fail to generate sales, the single-product dependence will remain.

11

What to watch next

  1. December 30, 2026

    The conversion period for the perpetual convertible bonds opens. Full conversion would issue about 8.31 million shares (29.81%) and could change the largest shareholder's stake, so the scale of actual conversion requests is the point to confirm.

  2. Q4 2026 (by late December)

    This is the target window for the FDA submission for dRAST. Whether the filing is made, and the review timeline that follows, determines the next stage of US market entry.

  3. Late 2026

    This is the target for approval and launch of dRAST evo. Whether the stated cost reduction is reflected in selling prices and profitability is the point to check.

  4. By end-March 2027

    This is the statutory deadline for the fiscal 2026 annual report, when full-year revenue, operating loss and the capital structure after the perpetual bonds are confirmed in filings.

  5. 2027

    The planned name change to Cumico is scheduled for 2027. Whether the expanded business purposes turn into actual operations will show up in later filings.

12

Overall view

QuantaMatrix recorded operating losses in each of the four years from 2022 through 2025 on a single-product revenue base, and the losses have continued for five straight quarters through the third quarter of 2026.

Revenue rose 47.7% to KRW 3.69 billion in 2025, and the operating margin improved from -1,556.7% in 2022 to -421.8% in 2025. The KRW 36 billion perpetual convertible bond decided in December 2025 lifted total equity to about KRW 40 billion and reduced financial risk.

Bull points are the dRAST evo cost plan, the pipeline expansion including Alzplus, and KRW 28 billion of unused funds. Bear points are the first-half 2026 revenue decline and wider losses, doubts over whether the expanded business scope will work, and possible dilution from conversion.

The conversion period opens on December 30, 2026, and the FDA submission target in the fourth quarter of 2026 and the dRAST evo approval target in late 2026 are the next checkpoints.

The fiscal 2026 annual report is due by end-March 2027, when full-year results and the capital structure will be confirmed again in filings.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. bloter.net
  4. m.news.nate.com
  5. m.news.nate.com
  6. hankyung.com
  7. ibtomato.com
  8. biotimes.co.kr
  9. m.thebell.co.kr
  10. vegannews.co.kr
  11. job-post.co.kr
  12. m.news.nate.com
  13. v.daum.net
  14. quantamatrix.com
  15. bosa.co.kr
  16. comp.wisereport.co.kr
  17. markets.hankyung.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis